Abstract: The invention pertains to a method to purify coccidial oocysts having dimensions between Dmin and Dmax from faeces comprising the steps of collecting the faeces containing the coccidial oocysts from host animals, diluting the faeces in an aqueous medium, separating a coarse fraction comprising macroscopic particulate matter from the diluted faeces and collecting an aqueous fraction containing the oocysts, characterised in that the method further comprises sieving the aqueous fraction over a first sieve deck having mesh openings to let the oocysts pass, to obtain an aqueous filtrate comprising the oocysts and a first residue comprising particles larger than the oocysts, and sieving the aqueous filtrate over a second sieve deck having mesh openings to obstruct passing of the oocysts through this sieve deck, to obtain a second residue comprising the purified oocysts and a waist filtrate comprising particles smaller than the oocysts.

Abstract: The invention pertains to a method to sporulate coccidial oocysts purified from animal faeces (5), the method comprising providing the purified oocysts as a layer (40) on a supporting surface (22), maintaining the layer at least intermittently in an oxygen containing gaseous environment (60) having a relative humidity of at least 15% and maintaining the temperature of the oocysts between 19° C. and 37° C. The invention also pertains to sporulated oocysts obtained with this method and to a vaccine containing such sporulated oocysts.

Abstract: The invention pertains to a method to purify coccidial oocysts having dimensions between Dmin and Dmax from faeces comprising the steps of collecting the faeces containing the coccidial oocysts from host animals, diluting the faeces in an aqueous medium, separating a coarse fraction comprising macroscopic particulate matter from the diluted faeces and collecting an aqueous fraction containing the oocysts, characterised in that the method further comprises sieving the aqueous fraction over a first sieve deck having mesh openings to let the oocysts pass, to obtain an aqueous filtrate comprising the oocysts and a first residue comprising particles larger than the oocysts,and sieving the aqueous filtrate over a second sieve deck having mesh openings to obstruct passing of the oocysts through this sieve deck, to obtain a second residue comprising the purified oocysts and a waist filtrate comprising particles smaller than the oocysts.

Abstract: The invention pertains to a method to sporulate coccidial oocysts purified from animal faeces (5), the method comprising providing the purified oocysts as a layer (40) on a supporting surface (22), maintaining the layer at least intermittently in an oxygen containing gaseous environment (60) having a relative humidity of at least 15% and maintaining the temperature of the oocysts between 19° C. and 37° C. The invention also pertains to sporulated oocysts obtained with this method and to a vaccine containing such sporulated oocysts.

Abstract: The present invention generally relates to the fields of parasitology and immunology, and especially to a vaccine against Rhipicephalus ticks. In particular the invention relates to a composition comprising a first and a second protein, in particular Bm86 and Subolesin proteins, including their homologs or immunogenic fragments; to the use of such a composition as a vaccine against Rhipicephalus ticks, and to the use of the first and the second isolated proteins for the vaccination of a target against Rhipicephalus ticks.

Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.

Abstract: The present invention generally relates to the fields of parasitology and immunology, and especially to a vaccine against Rhipicephalus ticks. In particular the invention relates to a composition comprising a first and a second protein, in particular Bm86 and Subolesin proteins, including their homologs or immunogenic fragments; to the use of such a composition as a vaccine against Rhipicephalus ticks, and to the use of the first and the second isolated proteins for the vaccination of a target against Rhipicephalus ticks.

Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.

Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.

Abstract: The invention relates to Babesia proteins of a 28kDa protein family and to immunogenic fragments of such proteins, to nucleic acids encoding such proteins or fragments, to cDNA fragments, recombinant DNA molecules, live recombinant carriers, or host cells comprising such nucleic acids, to vaccines, to methods for the preparation of such vaccines, to the use of such proteins or fragments for the prophylactic or therapeutic treatment of an infection or its clinical signs caused by an organism of the family Babesiidae, and to diagnostic tests for detection of nucleic acids, antibodies or antigens of an organism of the family Babesiidae.

Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.

Abstract: The present invention relates to coccidia strains and, in one embodiment, to microbiological cultures comprising such strains. In preferred embodiments, the coccidia strains are selected for tolerance to one group of coccidiostatic drugs, sensitivity to a second group of coccidiostatic drugs, and decreased proliferative capacity. Another embodiment of the invention relates to vaccines based on the coccidia strains according to the invention.

Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.

Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.

Abstract: The present invention relates to coccidiosis strains and, in another embodiment to microbiological cultures comprising such strains. Another embodiment of the invention relates to vaccines based thereon. Still other embodiments relate to the use of such strains for the preparation of vaccines for the protection against coccidiosis and to methods for the preparation of such vaccines.

Abstract: The invention is directed to a vaccine comprising Babesia canis antigens from a strain of Babesia canis rossi and another Babesia canis subspecies.Such a vaccine gives both homologous protection, and heterologous protection to infection with strains other than those of which the antigens have been isolated.Preferably the antigens are soluble antigens which can be harvested from the supernatant of a culture of Babesia parasites.